Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions

R Bai, GF Taylor, JM Schmidt, MD Williams, JA Kepler, GR Pettit and E Hamel

Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

We have prepared [3H]dolastatin 10 and examined its interactions with tubulin. Binding kinetics appeared to be biphasic, with a rapid initial reaction that could not be accurately measured, followed by a slower second reaction. Bound drug was stable in centrifugal gel filtration, column gel filtration, and high performance liquid chromatography gel filtration, but the bound drug could be displaced by an active isomer of dolastatin 10. Scatchard analysis of binding data was consistent with two classes of binding sites. However, dolastatin 10 induced an aggregation reaction upon binding to tubulin, complicating analysis of the data, and incorporation of [3H]dolastatin 10 into large aggregates was readily demonstrated. The chromatographic properties of the smallest radiolabeled species that could be documented were most consistent with a complex consisting of two molecules of alpha/beta- tubulin dimer and two molecules of [3H]dolastatin 10. The coexistence of an aggregation reaction with a binding reaction at a single site probably underlies the biphasic binding kinetics and the biphasic Scatchard plot. Of peptides that strongly inhibit tubulin polymerization (dolastatin 10, dolastatin 10 isomers, segments, and analogs, dolastatin 15, and phomopsin A), only those previously shown to be strong inhibitors of vinblastine binding and nucleotide exchange also strongly inhibited [3H]dolastatin 10 binding and induced tubulin aggregation (dolastatin 10 itself, two chiral isomers of dolastatin 10, and phomopsin A). The morphology of dolastatin 10-induced aggregates was compared with that of vinblastine-induced aggregates under a variety of reaction conditions. With both drugs the aggregates had a more organized appearance when microtubule-associated proteins were included in the reaction.

Volume 47, Issue 5, pp. 965-976, 05/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. A. Dabydeen, J. C. Burnett, R. Bai, P. Verdier-Pinard, S. J. H. Hickford, G. R. Pettit, J. W. Blunt, M. H. G. Munro, R. Gussio, and E. Hamel Comparison of the Activities of the Truncated Halichondrin B Analog NSC 707389 (E7389) with Those of the Parent Compound and a Proposed Binding Site on Tubulin Mol. Pharmacol., December 1, 2006; 70(6): 1866 - 1875. [Abstract] [Full Text] [PDF]

				M. A. Jordan, K. Kamath, T. Manna, T. Okouneva, H. P. Miller, C. Davis, B. A. Littlefield, and L. Wilson The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol. Cancer Ther., July 1, 2005; 4(7): 1086 - 1095. [Abstract] [Full Text] [PDF]

				R. Bai, D. G. Covell, G. F. Taylor, J. A. Kepler, T. D. Copeland, N. Y. Nguyen, G. R. Pettit, and E. Hamel Direct Photoaffinity Labeling by Dolastatin 10 of the Amino-terminal Peptide of {beta}-Tubulin Containing Cysteine 12 J. Biol. Chem., July 16, 2004; 279(29): 30731 - 30740. [Abstract] [Full Text] [PDF]

				Z. Cruz-Monserrate, H. C. Vervoort, R. Bai, D. J. Newman, S. B. Howell, G. Los, J. T. Mullaney, M. D. Williams, G. R. Pettit, W. Fenical, et al. Diazonamide A and a Synthetic Structural Analog: Disruptive Effects on Mitosis and Cellular Microtubules and Analysis of Their Interactions with Tubulin Mol. Pharmacol., June 1, 2003; 63(6): 1273 - 1280. [Abstract] [Full Text] [PDF]

				U. Vaishampayan, M. Glode, W. Du, A. Kraft, G. Hudes, J. Wright, and M. Hussain Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma Clin. Cancer Res., November 1, 2000; 6(11): 4205 - 4208. [Abstract] [Full Text] [PDF]

				N. R. Watts, D. L. Sackett, R. D. Ward, M. W. Miller, P. T. Wingfield, S. S. Stahl, and A. C. Steven HIV-1 Rev Depolymerizes Microtubules to Form Stable Bilayered Rings J. Cell Biol., July 24, 2000; 150(2): 349 - 360. [Abstract] [Full Text] [PDF]

				P. Verdier-Pinard, J. A. Kepler, G. R. Pettit, and E. Hamel Sustained Intracellular Retention of Dolastatin 10 Causes Its Potent Antimitotic Activity Mol. Pharmacol., January 1, 2000; 57(1): 180 - 187. [Abstract] [Full Text]

				C. Dumontet and B. I. Sikic Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death J. Clin. Oncol., March 1, 1999; 17(3): 1061 - 1061. [Abstract] [Full Text] [PDF]